Overview

* Prelude Q3 2025 net loss narrows to $19.7 mln from $32.3 mln year-over-year

* Company reports cash runway into 2027 after receiving $60 mln from Incyte

* Lead candidates from JAK2V617F and KAT6A programs advancing to clinical trials

Outlook

* Prelude anticipates filing IND for JAK2V617F inhibitor in first half of 2026

* Company expects cash runway to extend into 2027

* Prelude plans IND filing for KAT6A degrader program by mid-2026

Result Drivers

* JAK2V617F PROGRAM - Lead candidate advancing with IND filing expected in Q1 2026, targeting mutation in myeloproliferative neoplasms

* KAT6A PROGRAM - Lead candidate advancing with IND filing expected in mid-2026, focusing on ER+ breast cancer

* DAC COLLABORATION - Expanded scope with AbCellera Biologics, enabling use of degrader payloads on additional targets

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.26

Q3 Net -$19.73

Income mln

Q3 -$20.42

Income mln

from

Operatio

ns

Q3 $26.92

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Prelude Therapeutics Inc ( PRLD ) is $4.00, about 66.3% above its November 11 closing price of $1.35

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)